Author Archives: admin


Sartorius and Science to award a prize for regenerative medicine and cell therapy – EPM Magazine

The Sartorius and Science Prize for Regenerative Medicine & Cell Therapy is focused towards scientists advancing research (basic or translational) within the relevant fields, with the winner receiving $25,000 in prize money and being published inScience magazine.

Scientists who have gained a PhD or an MD during the past decade are invited to submit an essay on regenerative medicine, cell therapy, gene therapy or immunotherapy, as well as on materials or tissue engineering. The essays should be 1,000 words in length and should describe the applicants research and implications for regenerative medicine and cell immunotherapy, as well as include supporting documents.

In addition to the cash prize and publication in Science, the winner will receive a Sartorius product package for free. Furthermore, up to three runner-up essays will be published in Science Online and the writers of the runner-up essays will also receive a cash prize of $5,000.

This area [regenerative medicine and cell therapy] will play a major role in the future, said Gerry MacKay, member of the Sartorius Group executive committee and executive vice president of marketing, sales and services for Sartorius Lab Products & Services Division. Sartorius innovative bioanalytical tools help scientists answer fundamental and complex biological questions. We are excited to enable medical progress in these fields, both with our technologies and this award. The prize will be conferred as a token of appreciation to scientist.

Science is delighted to join Sartorius in awarding a prize in the exciting area of regenerative medicine and cell therapy, added Valda J. Vinson, deputy editor research of Science. We look forward to promoting basic or translational research in fields ranging from gene therapy to materials engineering, which has the potential to improve human health.

Applications will be accepted until 1 October and the awards ceremony will be held in 2018 in Goettingen, Germany.

Link:
Sartorius and Science to award a prize for regenerative medicine and cell therapy - EPM Magazine

Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease – Twin Cities Business Magazine

A regenerative medicine startup led by a Mayo Clinic cardiologist is setting up shop in a downtown Rochesters Minnesota BioBusiness Center, according to newly filed city documents. The filing indicated Rion LLC, a Minnesota company registered to Dr. Atta Behfar of the Mayo Clinic Center for Regenerative Medicine, has signed a three-year lease for just over 2,000 square feet at the city-owned BioBusiness Center. The lease begins July 1. The nine-story BioBusiness Center opened in downtown Rochester in 2007 as a center for innovation in biotechnology, promoting the linkages between the researchers and practitioners at Mayo Clinic; instructors and students at the University of Minnesota Rochester, and the biotechnology business community. It houses the Mayo Clinic Business Accelerator among other tenants. Behfar is an assistant medical professor and leads a laboratory at Mayo concentrating on applying regenerative medicine the practice of using stem cells to regenerate damaged or missing tissue to prevent and cure chronic heart conditions. Specifically, his group focuses on development and use of both stem cells and protein-based therapies to reverse injury caused by lack of blood flow to the heart. The business direction of Rion, meanwhile, appears to be specifically geared toward a cutting-edge development in the field of regenerative medicine the use of extracellular vesicles (EVs) in speeding and directing the growth of regenerating tissues in the heart and elsewhere in the body. EVs, long brushed off by researchers as mere debris in the bloodstream, are membrane-enclosed spheres that break off from the surfaces of nearly all living cells when disturbed. They transport lipids, proteins and nucleic acids, and have now been found to be important players in cell-to-cell communication, influencing the behavior and even the identity of cells. Their emerging role in regenerative medicine could potentially be huge. For instance, by bioengineering them to transport protein payloads from stem cells, they can be used to signal the bodys own cells to regenerate tissue instead of transplanting the stem cells themselves, thus eliminating the chance of host immune system rejection. A patent application filed last year by Rion, Behfar, Mayo Center for Regenerative Medicine Director Dr. Andre Terzic and two other local inventors is aimed at adapting the healing properties of a specific type of EV into a unique kind of product that could have wide applications. It focuses on EVs derived from blood platelets, which are well known to stop bleeding, promote the growth of new tissues and blood vessels, relieve inflammation and provide a host of other benefits. The patent describes a system of encapsulating platelet EVs derived from human or animal blood into a platelet honey and delivering it to target areas of the body, such as damaged tissues or organs. Its purported effect is to regenerate, repair and restore damaged tissue, with possible uses including treating heart disease; healing damaged bones or joints; wound treatment; and cosmetic skin applications. A brief business description provided by Rion to Rochester city officials stated the company is focused on the delivery of cutting edge regenerative technologies to patients at low cost and in off-the-shelf fashion. Building on initial research at Mayo Clinic, Rion LLC aims to develop and bring to practice products in the space of wound healing, orthopedics and cardiac disease. The statement also added the company is an enthusiastic backer of Rochesters efforts to develop a local biotech business cluster, and is seeking to participate in the realization of the Destination Medical Center initiative.

Follow this link:
Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease - Twin Cities Business Magazine

7th International Conference and Exhibition on Cell and Gene Therapy – Technology Networks

Conference Series LLC welcomes you to attend the 7th International Conference and Exhibition on Cell & Gene Therapy during March 15-17, 2018 at London, UK. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cell & Gene Therapy.

Cell and Gene Therapy Conference is to ameliorate the knowledge, awareness, and education on cell and gene therapy leading to the discovery of genetic and cellular therapies which aid to alleviate the human disease as it is the most significant emerging technology in the eyes of Medical, Biotechnology, Pharmaceuticals and Academia. Cell and Gene Therapy Conference 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Cell Therapy Conferences will provide a perfect platform to all the Doctors, Researchers Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Gene Therapy Conferences strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

This three-day Gene Therapy Event will address key issues concerning cell and gene therapy in the broader context of cellular and genetic disorder. Organized around daily themes, the Conference focuses on moving from present knowledge to future solutions

For more details: http://cellgenetherapy.conferenceseries.com/

Contact:

Angelica Kenova

Email: celltherapy@conferenceseries.net

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Continued here:
7th International Conference and Exhibition on Cell and Gene Therapy - Technology Networks

AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.

The company said it enrolled the first patient with acute myeloid leukaemia (AML) to be treated with UCART123 at Weill at Cornell Medicine, New York Presbyterian Hospital. UCART123 is a TALEN-genome edited chimeric T cell receptor targeting the CD123/IL3R antigen on the surface of blasts and dendric cells, which is administered on allogeneic donor T cells. The team of Gail J. Roboz will investigate the safety and will collect first indications for efficacy of UCART123 in patients with AML. The Phase I trial is part of a strategic translational research alliance that was formed between Cellectis and Weill Cornell Medicine in 2015.

While Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in contrast to the autologous patient T cells. Those need to be isolated, engineered and expanded during the at least 14 day hospital stay of the patients to be treated making the procedure costly, lengthy and laborious. On the other hand, Cellectis therapy does not target the CD19 T cell antigen but CD123//IL3R giving the company another unique selling point.

Cellectis has used TALEN technology to block expression of the TCRa constant (TRAC) gene though blocking expression of the natural TCR. According to Andr Choulika, Cellectis CEO, TALEN technology shows less off-target effects compared to CRISPR/Cas9 genome editing. Following apheresis, donor T cells are engineered to express an anti-CD123 CAR (CD123 scFv-41BB-CD3z) and an RQR8 depletion ligand that confers susceptibility to rituximab. Theoretically, specifity of of UCART123 therapy might be higher in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) than in patients with AML as CD123 expression is 10fold higher in the precursors of plasmacytoid dendritic cells than in blast occurring in the course of AML.

Cellectis also announced two new entries to ists Board of Directors. Ex-Novartis pharma division head Rainer Boehm will lead commercialisation of Cellectis lead candidate. Ex Novartis Oncology President and Incyte Corp CEO Herv Hoppenot will lead clinical development.

View original post here:
AML: Cellectis testing allogenic CAR-T cell therapy - European Biotechnology

Stem-cell treatment arrives in Kamloops – Merritt Herald

Photo courtesy of Kamloops This Week.

By: Jessica Wallace (Kamloops This Week)

Gail Walsh didnt want to spend the rest of her days waiting.

The 72-year-old retired Peachland woman said she needed surgical procedures on both knees, hip, neck and back, but didnt want to sit on the waiting list. Instead, she researched alternatives and learned about a doctor in Kelowna offering private stem-cell treatment.

The retired teachers aid committed $6,500 with the hopes of checking some items off her list of procedures.

I thought, I can just see the rest of my days, waiting for surgery after surgery, then recuperating in between, Walsh told KTW. It just seemed to me it was worth the money to try.

Helping people on wait lists is among reasons why a longtime Kamloops neurosurgeon recently began offering stem-cell treatment, despite the fact the procedure is not approved by Health Canada.

The expense [of stem-cell treatment], itll never be offered in the public system, so Canada will be behind the rest of the world, Dr. Richard Brownlee told KTW.Lots of people will do medical tourism, theyll go to Mexico or the States or Germany or whatever to get treatment thats not available here. Wait lists are the other thing.People wait for a year to get a MRI, so if they dont have to wait, they can come in and get one in less than a week or two.

The Welcome Back Centre, a private pain-management clinic on Columbia Street, began offering stem-cell treatment three months ago.

Stem cells are prevalent in humans and can be extracted to help treat degenerative, inflammatory or autoimmune conditions, Brownlee said.

Under the right conditions, stem cells can adapt into other cells. Someone with arthritis may have stem cells injected into a joint to create new cartilage, while athletes may treat soft tissue after a muscle tear, he said.

Brownlee noted the medicine is evolving, even being used to slow down symptoms of but not cure amyotrophic lateral sclerosis (ALS/Lou Gehrigs Disease.)

Stem cells are what do the repairing, Brownlee said. So, if youre putting a big number of those locally at the site of where the injury is, it just encourages healing.

Controversy has surrounded embryonic stem-cell harvest from fetuses. Brownlee said it is both unethical and risky, being that young cells have the potential to change into anything, including cancer.

Much like organ transplant, there is also the risk of the body rejecting them. Brownlees office extracts stem cells from the adults who are receiving them.

If youre taking it directly from the person and processing it and putting it right back in, theres no issues with it, he said.

Brownlee said stem-cell treatment is ideal for people who either havent healed adequately or who have developed degenerative changes over time. Ranging from $5,000 to $10,000 per treatment, it is often sought as a last resort.

The centre has treated about a half-dozen knees and hips and is expanding into other treatments.

Nothing has 100 per cent effectiveness, but most of the conditions, about 85 per cent of people get benefit, Brownlee said.

In offering the first treatment of its kind in the city, Brownlee is educating the public and keeping up with new developments. He just got back from a conference in Beverly Hills through the Cell Surgical Network and said he is looking at joining the group to gain access to data from more than 7,000 cases.

Its just new and different and its something that will probably never be offered through the public system, he said.

As for Walsh, seven weeks after her first treatment, she said its too early to determine if the procedure was successful. Relief could take up to nine months.

All I know is so far, theres nothing harmful done, she said.

Future of stem cells

While Dr. Richard Brownlee said stem-cell treatment will likely never be offered publicly, Prime Minister Justin Trudeau last year announced $20 million in funding to the Centre for Commercialization of Regenerative Medicine to help establish a stem-cell therapy development facility in Toronto.

Regenerative medicine is the future and not only is it the future, its a branch of medicine that Canada and the province of Ontario are actually quite good at, Trudeau was quoted at the time in a story in the Globe and Mail about the announcement.

The medical advances and innovations happening right here in Toronto are world class.

Common applications:

Knees: partial to complete ligament tears, osteoarthritis, partial to complete meniscal tears, augmented ACL or PCL reconstruction;

Shoulder: partial to complete rotator cuff tears, labral tears, osteoarthritis;

Foot and ankle: tendon inflammation, osteoarthritis, patron to complete Achilles tendon tear;

Elbow, wrist and hand: partial to complete ligament tears, epicondylitis, osteoarthritis;

Spine: discogenic back pain, facet arthritis, degenerative disc disease;

Hip: osteoarthritis, labral tears, articular cartilage injuries, avascular necrosis.

Did you know?

Stem cells can be injected locally or delivered intravenously.

Gordie Howe underwent stem-cell therapy after having a stroke and responded well. His family said it helped him walk again, improved his speech and helped him gain weight.

Fat contains 100 to 1,000 times more stem cells than bone marrow.

Excerpt from:
Stem-cell treatment arrives in Kamloops - Merritt Herald

Plastic Surgery Junkie Melanie Tries Stem Cell Treatments In Bid To Turn Back Time – Radar Online

Aging actress Melanie Griffith has turned to unproven and risky science in a desperate bid to turn back the clock!

RadarOnline.com has learned plastic surgery junkie Griffith recently returned to the mysterious ACQUA Klinik in Germany for the second time in six months for stem cell treatments.

The clinic claims the procedure will bring back the fullness and elasticity of your skin, minimize wrinkles and activate hair growth on your head.

PHOTOS: Fab At 58? Melanie Griffiths Lumps & Bumps Exposed In Blue Bikini

Melanie is crazy about the treatment! a source close to the Working Girl star who turns 60 in August revealed. Shes convinced that the clinics special therapy actually turns back time! She believes it replenishes and rejuvenates her skin, using her own cells, so she looks young again!

The clinic offers the Hollywood Aesthetics program developed by Dr. Augustinus Bader, a professor of stem cell technology, whos reportedly developed a miracle cure for aging.

The program is touted as a groundbreaking system that reactivates endogenous stem cells and renews the skin via a miracle hydrogel.

PHOTOS: They Said It! The 24 Most Explosive & Bizarre Celebrity Interviews Ever

Using an ointment instead of a scalpel to turn back the hands of time sounds tempting, especially for Melanie, who has been a victim of botched cosmetic procedures for years, one insider revealed.

The once fresh-faced actress has admitted to having a breast lift and collagen injections.

But Griffith, who has battled drug and booze demons, appears to have done much more, according to experts.

PHOTOS: How Bizarre! 20 Kooky, Crazy Celebrity Conspiracy Theories

I believe shes had both her upper and lower eyelids done, plus a brow lift and chin implant, said plastic surgeon Dr. Brian Glatt, who has not treated the star.

Cosmetic surgeon Dr. Anthony Youn, who has also not worked with Griffith, believes the four-time divorce also had cheek enhancements, as well as plumping thats left her with duck lips.

Griffith has insisted she quit going under the knife years ago, and she has tried to claim she had no clue how drastically cosmetic procedures had changed her face.

PHOTOS: Solanges Erratic Elevator Beat-Down Of Jay Z Isnt The First Time Shes Shocked: A Look Back At Some Of Her Most Bizarre Moments

No, I didnt [realize] until people started saying, Oh, my God! What has she done? I was so hurt, Griffith recalled.

I went to a different doctor, and he started dissolving all of this st that this other woman doctor had put in. Hopefully, I look more normal now.

However, expert Dr. Gabe Mirkin, who hasnt treated the star, warned Melanie could be sorely disappointed: Unchanged stem cells by themselves have not been proven to cure disease or prolong lives.

We pay for juicy info! Do you have a story for RadarOnline.com? Email us at tips@radaronline.com, or call us at (866) ON-RADAR (667-2327) any time, day or night.

Follow this link:
Plastic Surgery Junkie Melanie Tries Stem Cell Treatments In Bid To Turn Back Time - Radar Online

TissueGene Awarded $750000 Maryland Stem Cell Grant for Invossa Clinical Study – PR Newswire (press release)

TissueGene has been awarded a $750,000 clinical grant from the Maryland Technology Development Corporation (TEDCO) via the MSCRF. The clinical grant is to be used for conducting clinical trials in Maryland using cell therapy. This money is part of Accelerating Cure, a new TEDCO initiative to support regenerative medicine and cell therapy technologies in Maryland.

The grant award will be used by TissueGene to fund a component of a clinical study at a Maryland location for its US Phase III clinical trial for Invossa. The ultimate outcome of this study is the verification that Invossa exerts its therapeutic effect not only by tissue regeneration but on other inflammatory aspects of the disease such as synovitis.

The title of the grant is "Assessment of the Efficacy of TG-C in Treating Synovitis Using Contrast Enhanced MRI in a Clinical Study of Knee Osteoarthritis." The Principal Investigator (PI) for the study will be Dr. Gurdyal Kalsi, Chief Medical Officer of TissueGene.

"We are excited to support this important clinical trial and the growth of TissueGene in Maryland," said Dr. Dan Gincel, TEDCO's VP University Partnerships, and MSCRF's Executive Director. "We look forward to see many more patients treated and cured from this and other devastating diseases."

Woosok Lee, CEO of TissueGene stated, "As a Maryland-based company, TissueGene is honored by the grant award from the State of Maryland which has consistently demonstrated its commitment to supporting innovative therapies such as Invossa, which could potentially be the world's first disease-modifying drug for treating osteoarthritis."

Invossa is a first-in-class osteoarthritis drug designed to conveniently and effectively treat osteoarthritis of the knee through a single intra-articular injection. Clinical trials completed in Korea and on-going trials in the US have demonstrated pain relief, increased mobility, and improvements in joint structure offering substantial convenience for the nearly 33 million Americans with osteoarthritis who would otherwise be in need of surgery.

TissueGene, Inc. TissueGene, Inc., is a Maryland-based regenerative medicine company specializing in cell and gene therapy. TissueGene's lead product is Invossa, an allogeneic, cell and gene therapy for osteoarthritis of the knee that has completed Phase II clinical trials in the US. TissueGene has recently reached an agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment (SPA) for a Phase 3 clinical trial for Invossa. Information can be found at the NIH registry, ww.clinicaltrials.gov. For additional information about TissueGene, Inc., please visit http://www.tissuegene.com.

The Maryland Stem Cell Research Fund (MSCRF) was established by the State of Maryland under the Maryland Stem Cell Research Act of 2006 to promote State-funded stem cell research and cures through grants and loans to public and private entities in the State. Administered by The Maryland Technology Development Corporation (TEDCO), the MSCRF is overseen by an independent Commission that sets policy and develops criteria, standards and requirements for applications to the Fund. For more information about the Maryland Stem Cell Research Fund, please visit http://www.mscrf.org.

The Maryland Technology Development Corporation (TEDCO) is the go-to source for entrepreneurial support and guidance for technology start-ups and early-stage companies engaged in bringing innovative ideas to market. For over nineteen years, the organization has provided funding, mentoring and networking opportunities to support Maryland's innovation ecosystem. It is frequently ranked as one of the most active seed/early-stage investors in the nation. The organization plays a key role in bringing research created in Maryland's educational institutions and federal laboratories into the commercial marketplace. For more information on TEDCO and its programs and resources, visit http://www.TEDCO.md.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tissuegene-awarded-750000-maryland-stem-cell-grant-for-invossa-clinical-study-300482506.html

SOURCE TissueGene, Inc.

http://www.tissuegene.com

Read this article:
TissueGene Awarded $750000 Maryland Stem Cell Grant for Invossa Clinical Study - PR Newswire (press release)

New Texas Law on Stem Cell Treatments: Showdown With FDA Coming? – Regulatory Focus

Posted 28 June 2017 By Zachary Brennan

With a new Texas law now in the books to allow companies to sell unproven stem cell treatments without US Food and Drug Administration (FDA) approval, some experts wonder when FDA will step in to shut down companies and clinics exposing people to unapproved medical products.

Similar to the Right to Try laws spreading across the US and attempting to undercut FDAs regulation of investigational products, the Texas law, which had been brewing in some form since 2012, applies to certain investigational stem cell treatments for patients with certain severe chronic diseases or terminal illnesses.

And though the Texas law says that it applies to stem cell treatments currently under investigation in clinical trials, it also blocks the Texas Medical Board from revoking, failing to renew or suspending a physicians license based solely on the physicians recommendations to an eligible patient regarding access to or use of an investigational stem cell treatment.

An investigation by Nature in 2012 uncovered unproven and costly stem cell treatments being sold in Texas.

Leigh Turner, anassociate professorat the University of Minnesotas Center for Bioethics and School of Public Health and co-author of a paper in Cell on the selling of stem cell therapies directly to US consumers, explained to Focus the unpredictable nature of Texas law, as the state already has one of the highest concentrations of unregulated stem cell clinics (California and Florida also have high concentrations of such clinics, he said, noting his investigation found more than 500 such clinics in the US).

There are lots of credible stem cell researchers in Texas, but theyre not the ones pushing for this bill, Turner said, noting that the greatest concern should be focused on clinics offering unproven stem cell treatments for a range of diseases with few or no treatment options, like ALS, autism, spinal cord injuries and others.

And though there are provisions in the bill that, according to Turner, could knock some businesses out of the marketplace in Texas, he said its hard to know which way itll break, though it seems clearly based on the fantasy that Texans have to go elsewhere to receive these investigational stem cell therapies.

FDA has so far let these direct-to-consumer stem cell clinics flourish and has only issued a limited number of warning letters to companies like Cell Vitals in 2014, Irvine Stem Cell Treatment Center in 2015 and Lavian in 2016.

Former FDA Commissioner Robert Califf, Center for Biologics Evaluation and Research Director Peter Marks and CBER Deputy Director Celia Witten in December 2016 made the case in the New England Journal of Medicine that the hype over such treatments outpaces the evidence that they are safe and effective, though the agency has not cracked down on the direct-to-consumer stem cell market.

FDA couldve done something since 2009, this is a marketplace thats been around a while, Turner said.

And because many of the clinics engage in interstate commerce, Turner said they do clearly fall within FDAs jurisdiction. But its not just FDA, he added, the Federal Trade Commission could also act, as could state consumer protection agencies or state medical boards.

So why isnt FDA taking action? The agency did not respond to a request for comment and Turner said he has not received a straight answer from the agency.

Will they knock out these businesses? Talking with FDA, I didnt hear that, he said, adding that he did not get the impression that theres a comprehensive, organized plan to deal with the emergence of such a large and growing marketplace.

Read more:
New Texas Law on Stem Cell Treatments: Showdown With FDA Coming? - Regulatory Focus

U team discovers ‘powerhouse’ new treatment in fight against deadly skin disease – Southernminn.com

Jonathan Pitre is a teenager who loves to write science fiction as an escape from the painful disease that causes his body to be coated with wounds.

But the breakthrough bone-marrow transplant he just received at the University of Minnesota is anything but fantasy.

A decade after performing the worlds first bone marrow transplants to treat epidermolysis bullosa a rare and potentially fatal skin disease university researchers believe they have discovered a powerhouse new formula that advances their research, helps the body grow new skin and will allow patients such as Pitre, 17, to live longer, less painful lives.

Its really not miraculous. It certainly isnt science fiction, said Dr. Jakub Tolar, director of the Us stem cell institute and the world leader in transplant therapies for EB. Its based on the hard work of our predecessors. You accomplish something and then you use that knowledge to enhance the next step and the next step.

When they conducted the first transplants using donor bone marrow and umbilical cord blood in 2007, Tolar and colleagues were trying to produce a collagen that binds skin together and is lacking in EB patients. But they had little certainty about the types of cells that would work best.

Since then, research discoveries have allowed them to home in on mesenchymal stem cells, which they believe are uniquely good at bullying their way into the body and producing the missing collagen.

This is the first time ever, that I know of, when you are infusing them with the goal that these cells will stay, Tolar said. They will graft into the skin, set up shop there. Its as if these mesenchymal stem cells are coming home.

The doctors have also focused on transplants involving bone marrow from relatives, which is more familiar to the body and less likely to be rejected by the recipients.

A transplant like Jonathans occurs in a one-two punch. After receiving radiation and chemotherapy treatments to suppress the immune system, the patient receives an infusion of hematopoietic blood stem cells from a donor. Their job in this procedure is to give the patient a new immune system that wont reject the donors mesenchymal cells when they are transplanted later.

Since the U received federal approval last fall to offer the treatment experimentally, seven patients have undergone the procedure.

Tolar said all seven are progressing though Jonathan needed a second transplant this spring because the first one failed to knock out his old immune system.

Jonathan suffered an infection after his most recent transplant, which forced him to return to the hospital this month with high fevers and blisters on his face and mouth. Even so, Jonathans mother, Tina Boileau, said she has been taking pictures since the latest transplant to document the progress for her son, whose back is covered with wounds but for a healthy spot on his right shoulder blade.

Theyre actually in scabs, a sign of healing, said Boileau, who was the bone marrow donor for her sons transplant. Which Ive never seen before.

10 patients died

EB afflicts about one in every 30,000 to 50,000 people, though some forms are more severe than others. While it is known largely for the grotesque skin wounds it causes, the disease is often fatal because it leads to severe infections or skin cancers. It can also create internal wounds to the patients digestive tract, which impairs eating.

The desperation of children with the disorder and their families compelled the first transplants at the university in 2007. Even using the old approach, about two-thirds of patients saw improvements, but 10 of the first 30 recipients died from their diseases or complications of treatment.

The Us latest success with mesenchymal stem cells might end up being an incremental step. Earlier this year, Tolar and his colleagues published research showing success in an even more advanced therapy: laboratory testing using gene editing that can reprogram the patients cells to produce healthy skin cells and tissue.

Further successes could lead to clinical trials in which a patients own dysfunctional cells would be reprogrammed, preventing the need for chemotherapy and the replacement of their immune systems.

Before they came to the U, Boileau said, her son had run out of options. Managing his pain, once possible with over-the-counter Advil, had come to require opioid painkillers such as methadone. That made him groggy and complicated his already awkward life at school back home in Ottawa. Jonathan wasnt even able to eat lunch in the school cafeteria for fear of being accidentally bumped and suffering fresh wounds.

Then the Canadian government approved funding to make him his countrys first recipient of an experimental bone marrow transplant for EB. And his home community rallied to support the family. Among other things, he has visited with pro hockey players from the Ottawa Senators, which also issued a contract adding him to their scout staff.

After seeing the pain her son has endured, Boileau said shell never complain about a blister from new shoes. She marvels at his optimism and his use of science fiction reading and writing to escape.

Inspired by the success of Christopher Paolini, who wrote the acclaimed Eragon science fiction novel as a teen, Jonathan has resolved to write his own science fiction book about a teen who develops the ability to overcome EB. The project resulted in long visits and e-mail exchanges between Tolar and his patient about medicine and physics, because Jonathan wants his story grounded in reality.

Theyre almost soul mates, Boileau said.

Tolar said he enjoys the intellectual relationship and that his patient is providing an example of hope and teaching others about the disease: He may be the only person [who] can bring this kind of view to others, Tolar said.

Read more from the original source:
U team discovers 'powerhouse' new treatment in fight against deadly skin disease - Southernminn.com

A New Path for US Stem Cell Inc (OTCMKTS:USRM) – The Oracle Dispatch

US Stem Cell Inc (OTCMKTS:USRM) is working its way back after a fall last week after news broke the company abandoning RMAT designation for its Myocell product. There was a feeling that the FDA told the company that it was not going to happen and USRM tried to bury the press, but the market saw it and shares tanked.

Since then, shares have been slowly working their way back. The stock is near .06 and has scored a few rips since June 21st, when the price fell to .03. This is an early player in the industry and recently received some nice funding ($5 million from General American Capital Partners).

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. USRMs discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases.

According to company materials, US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

You can find outwhen $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Now that Plan B is in place; however, it is a little unclear of what the ceiling is for USRM. The company will now expand stem cell treatment centers and clinics in the U.S. The company, based in Florida, had recently expanded to Miami Beach, but now the plans call for truly national expansion. USRM will set up stem cell treatment centers in huge metropolitan areas like Dallas, Chicago, Atlanta and Denver. Moreover, the company has emphasized that it will focus squarely on revenue-generating programs that are treating patients right now.

USRMs press detailed the new path for the company: To be clear, U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOWwhich have successfully helped over 7000 patients thus far. Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world. In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients.

US Stem Cell Inc (OTCMKTS:USRM) caught a bad break but still has strong technology and experience to hedge against the tide. USRM is not a company to completely throw out and they carry a market cap of $22.81 million with 335.43 million shares outstanding. We will be providing updates as the company take shape. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Follow this link:
A New Path for US Stem Cell Inc (OTCMKTS:USRM) - The Oracle Dispatch